After DaVita fraud settlement, allegations of defense misconduct linger

The U.S. Department of Justice may have opted to avoid involvement in the recently settled fraud case against embattled dialysis provider DaVita Healthcare Partners Inc. because of allegations of witness tampering and false testimony, according to Reuters. DaVita agreed last week to pay $450 million as part of a settlement reached with a pair of whistleblowers who claimed the company improperly billed Medicare and Medicaid by ordering and intentionally wasting large vials of medicine. During the case, one DaVita witness admitted to lying under oath, and prosecutors claimed that another witness did the same after being improperly coached by the company's lawyers. Defense attorneys admitted to making "regrettable mistakes" once the two parties agreed on a settlement, but denied any wrongdoing. >> Read the full article at FierceHealthPayerAntiFraud

Suggested Articles

Telehealth company Amwell saw its stock spike 42% in its first day of trading Thursday after raising an outsized initial public offering.

A new report outlines major telehealth policy recommendations but one physician group says the changes don't go far enough to support doctors.

Two technology companies are working on rapid COVID-19 antigen tests that can be performed by people at home without involving a laboratory.